197 related articles for article (PubMed ID: 31933006)
41. Personalized Nanomedicine: A Revolution at the Nanoscale.
Fornaguera C; García-Celma MJ
J Pers Med; 2017 Oct; 7(4):. PubMed ID: 29023366
[TBL] [Abstract][Full Text] [Related]
42. The Nano-Bio Interactions of Nanomedicines: Understanding the Biochemical Driving Forces and Redox Reactions.
Wang Y; Cai R; Chen C
Acc Chem Res; 2019 Jun; 52(6):1507-1518. PubMed ID: 31149804
[TBL] [Abstract][Full Text] [Related]
43. Market entry of biosimilar low-molecular-weight heparins in Europe: opportunities and challenges.
Simoens S; Huys I
Semin Thromb Hemost; 2013 Apr; 39(3):250-7. PubMed ID: 23235959
[TBL] [Abstract][Full Text] [Related]
44. Nanopharmaceuticals for wound healing - Lost in translation?
Ashtikar M; Wacker MG
Adv Drug Deliv Rev; 2018 Apr; 129():194-218. PubMed ID: 29567397
[TBL] [Abstract][Full Text] [Related]
45. Scientific considerations for complex drugs in light of established and emerging regulatory guidance.
Holloway C; Mueller-Berghaus J; Lima BS; Lee SL; Wyatt JS; Nicholas JM; Crommelin DJ
Ann N Y Acad Sci; 2012 Dec; 1276():26-36. PubMed ID: 23193987
[TBL] [Abstract][Full Text] [Related]
46. The EU regulatory landscape of non-biological complex drugs (NBCDs) follow-on products: Observations and recommendations.
Klein K; Stolk P; De Bruin ML; Leufkens HGM; Crommelin DJA; De Vlieger JSB
Eur J Pharm Sci; 2019 May; 133():228-235. PubMed ID: 30953753
[TBL] [Abstract][Full Text] [Related]
47. Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity.
Pani L; Montilla S; Pimpinella G; Bertini Malgarini R
Expert Opin Biol Ther; 2013 Oct; 13(10):1343-6. PubMed ID: 23805906
[TBL] [Abstract][Full Text] [Related]
48. Scientific and Regulatory Considerations for Generic Complex Drug Products Containing Nanomaterials.
Zheng N; Sun DD; Zou P; Jiang W
AAPS J; 2017 May; 19(3):619-631. PubMed ID: 28116676
[TBL] [Abstract][Full Text] [Related]
49. Biosimilars in the United States: Emerging Issues in Litigation.
Wong AY; Rumore MM; Chan AW
BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
[TBL] [Abstract][Full Text] [Related]
50. [Biosimilars: regulatory status for approval].
Herrero Ambrosio A
Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
[TBL] [Abstract][Full Text] [Related]
51. Regulating nanomedicine - can the FDA handle it?
Bawa R
Curr Drug Deliv; 2011 May; 8(3):227-34. PubMed ID: 21291376
[TBL] [Abstract][Full Text] [Related]
52. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
53. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
54. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.
Farjadian F; Ghasemi A; Gohari O; Roointan A; Karimi M; Hamblin MR
Nanomedicine (Lond); 2019 Jan; 14(1):93-126. PubMed ID: 30451076
[TBL] [Abstract][Full Text] [Related]
55. What is unique about nanomedicine? The significance of the mesoscale.
Khushf G; Siegel RA
J Law Med Ethics; 2012; 40(4):780-94. PubMed ID: 23289680
[TBL] [Abstract][Full Text] [Related]
56. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study.
Eifler AC; Thaxton CS
Methods Mol Biol; 2011; 726():325-38. PubMed ID: 21424459
[TBL] [Abstract][Full Text] [Related]
57. Regulatory safety evaluation of nanomedical products: key issues to refine.
De Jong WH; Geertsma RE; Borchard G
Drug Deliv Transl Res; 2022 Sep; 12(9):2042-2047. PubMed ID: 35908133
[TBL] [Abstract][Full Text] [Related]
58. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
59. Nanomedicine: Principles, Properties, and Regulatory Issues.
Soares S; Sousa J; Pais A; Vitorino C
Front Chem; 2018; 6():360. PubMed ID: 30177965
[TBL] [Abstract][Full Text] [Related]
60. The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019.
Kang HN; Thorpe R; Knezevic I;
Biologicals; 2020 May; 65():1-9. PubMed ID: 32224101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
